Agios Pharma Increases Shares in Stock Incentive Plan

The latest announcement is out from Agios Pharma ( (AGIO) ).

At the 2025 Annual Meeting of Stockholders held on June 18, Agios Pharmaceuticals’ stockholders approved an amendment to the 2023 Stock Incentive Plan, increasing the number of shares available for issuance by 2,500,000. Additionally, the stockholders elected two directors, approved executive compensation, and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year, reflecting strong support for the company’s strategic direction.

The most recent analyst rating on (AGIO) stock is a Hold with a $56.00 price target. To see the full list of analyst forecasts on Agios Pharma stock, see the AGIO Stock Forecast page.

Spark’s Take on AGIO Stock

According to Spark, TipRanks’ AI Analyst, AGIO is a Neutral.

Agios Pharma’s overall stock score of 61 reflects a mix of strong technical indicators and promising future growth potential from product launches, balanced against current financial challenges and operational inefficiencies. The company’s strategic focus on pipeline advancement and financial independence supports a cautiously optimistic outlook.

To see Spark’s full report on AGIO stock, click here.

More about Agios Pharma

Agios Pharmaceuticals, Inc. operates in the biotechnology industry, focusing on the development of innovative therapies for genetically defined diseases. The company primarily develops small-molecule medicines targeting cancer and rare genetic disorders.

Average Trading Volume: 613,614

Technical Sentiment Signal: Buy

Current Market Cap: $2.07B

Find detailed analytics on AGIO stock on TipRanks’ Stock Analysis page.